National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 42719 [2016-15443]
Download as PDF
Federal Register / Vol. 81, No. 126 / Thursday, June 30, 2016 / Notices
Background Information on
NICEATM: NICEATM conducts data
analyses, workshops, independent
validation studies, and other activities
to assess new, revised, and alternative
test methods and strategies. NICEATM
also provides support for the
Interagency Coordinating Committee on
the Validation of Alternative Methods
(ICCVAM). The ICCVAM Authorization
Act of 2000 (42 U.S.C. 285l–3) provides
authority for ICCVAM and NICEATM in
the development of alternative test
methods. Information about NICEATM
and ICCVAM is found at https://
ntp.niehs.nih.gov/go/niceatm and
https://ntp.niehs.nih.gov/go/iccvam.
Dated: June 24, 2016.
John R. Bucher,
Associate Director, National Toxicology
Program.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by emailing the indicated licensing
contact at the National Heart, Lung, and
Blood, Office of Technology Transfer
and Development Office of Technology
Transfer, 31 Center Drive Room 4A29,
MSC2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
Confidential Disclosure Agreement may
be required to receive any unpublished
information.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
mstockstill on DSK3G9T082PROD with NOTICES
BILLING CODE 4140–01–P
ACTION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel.
Date: July 27, 2016.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892,
(Telephone Conference Call).
Contact Person: James T. Snyder, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities/
Room 3G31B, National Institutes of Health,
NIAID, 5601 Fishers Lane MSC 9823,
Bethesda, MD 20892–9823, (240) 669–5060,
james.snyder@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
Jkt 238001
[FR Doc. 2016–15443 Filed 6–29–16; 8:45 am]
HHS.
BILLING CODE 4140–01–P
20:01 Jun 29, 2016
Dated: June 24, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
AGENCY:
[FR Doc. 2016–15444 Filed 6–29–16; 8:45 am]
VerDate Sep<11>2014
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Multi-Photon Microscopy System
Configured for Multiview Non-Linear
Optical Imaging
This invention is a microscopy device
and system for multi-photon
microscopy utilizing multi-view
nonlinear optical imaging. Nonlinear
optical imaging remains the premier
technique for deep-tissue imaging in
which typically a multi photon
arrangement may be used to illuminate
and excite a sample. However, the
penetration depth, signal-to-noise ratio,
and resolution of this technique is
ultimately limited by scattering. The
present system addresses these issues by
sequential excitation of a sample
through three or more objective lenses
oriented at different axes intersecting
the sample. Each objective lens is
capable of focused sequential excitation
that elicits fluorescence emissions from
the excited sample, which is then
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
42719
simultaneously detected by each
respective objective lens along a
respective longitudinal axis. Including
multiple lenses will improve the
penetration depth and at the same time
decrease the loss of detail because of
scattering. The system also can
overcome losses in spatial resolution
because of the scattering of the
excitation and emission light.
Potential Commercial Applications:
—High resolution multi-photon
microscopy
—Deep tissue visualization
—Competitive Advantages:
—Improved signal-to-noise ratio
—improved spatial resolution
—Development Stage:
• Prototype
Inventors: Yicong Wu (NIBIB), Hari
Shroff (NIBIB), Jianyong Tang (NIAID),
Ronald Germain (NIAID).
Intellectual Property: HHS Reference
No. E–229–2015/0; U.S. Provisional
Patent Application 62/210,153 filed
August 26, 2015.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Dated: June 24, 2016.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2016–15441 Filed 6–29–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Member
Conflict SEP.
Date: July 6, 2016.
E:\FR\FM\30JNN1.SGM
30JNN1
Agencies
[Federal Register Volume 81, Number 126 (Thursday, June 30, 2016)]
[Notices]
[Page 42719]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-15443]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel.
Date: July 27, 2016.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892, (Telephone Conference Call).
Contact Person: James T. Snyder, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities/Room 3G31B, National Institutes of Health, NIAID, 5601
Fishers Lane MSC 9823, Bethesda, MD 20892-9823, (240) 669-5060,
james.snyder@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: June 24, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-15443 Filed 6-29-16; 8:45 am]
BILLING CODE 4140-01-P